Faiq Akhter, MD
Cardiovascular Disease · Springfield, OHNPI 1801896303
Payments from drug & device makers
Across 199 payments — averaging $2104.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$219K
- Janssen Research & Development, LLC$145K
- Bayer$42K
- GSK$5K
- Medtronic$2K
- Penumbra, Inc.$2K
- plus $4K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $218,618 |
| Janssen Research & Development, LLC | 23 | $144,977 |
| Bayer | 9 | $42,150 |
| GSK | 2 | $4,574 |
| Medtronic(2 entities) | 23 | $2,261 |
| Penumbra, Inc. | 5 | $1,769 |
| Boston Scientific | 17 | $1,433 |
| Abbott | 5 | $748 |
| Inari Medical, Inc. | 2 | $306 |
| Johnson & Johnson | 25 | $290 |
| Novartis | 11 | $218 |
| Actelion Pharmaceuticals US, Inc. | 4 | $216 |
| Sanofi-aventis U.S. LLC | 8 | $133 |
| Abiomed | 4 | $123 |
| Angiodynamics, Inc. | 2 | $110 |
| Lundbeck LLC | 5 | $78 |
| AstraZeneca | 3 | $76 |
| Regeneron Healthcare Solutions, Inc. | 5 | $74 |
| Pfizer | 4 | $70 |
| Boehringer Ingelheim | 5 | $66 |
| Shockwave Medical, Inc | 1 | $57 |
| Livanova USA, Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Terumo Medical Corporation | 1 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| GE HealthCare | 1 | $21 |
| Merck | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Elutia, Inc. | 1 | $12 |
How this compares
$418,696 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Springfield
- Akber MohammedSpringfield$1.6M
- Sayed Tariq RizviSpringfield$606K
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Bhola RamaMarion$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.